Risom et al. showed that a MEK and PI3K/mTOR inhibitor-driven drug-tolerant persistent state in breast cancer arises through distinct cell-state transitions which involves dynamic remodeling of open chromatin architecture [66], in contrast to simple Darwinian selection of pre-existing subpopulations. This evidence concerns the gene MAP2K7 and breast carcinoma.